Install
Your go-to source for the latest news in health, science and medicine. Sign up for STAT+ for exclusive analysis of biotech, pharma, and the life sciences.
- 203articles · 30d
- 19+ hour agolatest article
- Aug 16, 2026earliest in window
- 95%with images
- 246avg words
- Medical 150
- Health & Wellness 138
- Health 100
- Science & Technology 46
- Business & Industrial 37
- Economy, Business & Finance 22
- Politics 19
- Politics2 18
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
I’m a thoracic surgeon in New York City. For many of my patients, Sept. 11 is still not over
3+ day, 16+ hour ago (1035+ words) Retired New York City police officer John Aris sat in my office recently waiting for the results of his latest CT scan. Seven years earlier, I had removed part of his right lung because of cancer. Since then, every follow-up…...
Breast cancer pill from AstraZeneca misses mark in pivotal trial
2+ day, 10+ hour ago (204+ words) STAT is a media company focused on finding and telling compelling stories about health, medicine, and scientific discovery. We produce daily news, investigative articles, and narrative projects in addition to multimedia features, podcasts, and opinion pieces. We tell our stories…...
Cancer drug shortages keep disrupting patient care
3+ day, 4+ hour ago (146+ words) Meghana Keshavan is a biotech correspondent at STAT and co-writer of The Readout newsletter. She joined STAT in 2016. She has written about the life sciences industry for more than a decade. Before that, she worked for news outlets like Thomson…...
Platinum-based chemotherapy in childhood causes mutations that age the liver
3+ day, 23+ hour ago (293+ words) Platinum-based chemotherapy — in particular cisplatin and carboplatin — are a lifeline for children with certain cancers. These treatments, for instance, transformed the prognosis of hepatoblastoma, a rare cancer of the liver that is the most commonly diagnosed in childhood, from a…...
FDA expands Bayer lung cancer drug approval
4+ day, 4+ hour ago (183+ words) Today, we look at how regulators are trying to keep pace with agentic medical AI, see the FDA launch a project to examine why pregnancy registries struggle with enrollment, and more. Someone out there cure asthma, eh? It sucks. John…...
Cancer medicines remain in short supply across the U.S., survey finds
4+ day, 4+ hour ago (256+ words) Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for more than three decades. His stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is…...
Kura cancer drug discovery spurs launch of a diabetes biotech
5+ day, 6+ hour ago (195+ words) Leukemia drug data suggested a different way to treat diabetes. A new biotech will test that idea STAT Leukemia drug data suggested a different way to treat diabetes. A new biotech will test that idea Kura Oncology turns experimental therapy…...
FDA approves AstraZeneca breast cancer drug
6+ day, 3+ hour ago (148+ words) Meghana Keshavan is a biotech correspondent at STAT and co-writer of The Readout newsletter. She joined STAT in 2016. She has written about the life sciences industry for more than a decade. Before that, she worked for news outlets like Thomson…...
Inhibrx claims first win for long-sought immunotherapy target
6+ day, 6+ hour ago (136+ words) statnews.com Inhibrx said Tuesday that its experimental immunotherapy targeting a protein called OX40 showed responses in patients with head and neck cancer. But the most striking results were in a small subset of patients with HPV-positive tumors, which could significantly…...
An administrative gap delays access to new pancreatic cancer treatment
6+ day, 6+ hour ago (533+ words) This does mean I’ll be stepping down from my daily newsletter soap box, though you’ll still hear from me every Wednesday. For the other weekdays, we’ll have a rotation of staff members writing the newsletter, led by editor-writer extraordinaire Amanda…...